FDA advisory panel rejects J&J drug for acute coronary syndrome
(Reuters) - Johnson & Johnson's anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.
The panel voted 10 to 0, with one abstention, against approval, saying data from a single clinical trial was not strong enough to justify approval, especially since some data from the trial was missing.
Xarelto is already used to treat and prevent deep vein thrombosis and pulmonary embolisms and to reduce the risk of stroke and blood clots in patients with an irregular heart beat that is not caused by heart problems.
- Tape emerges of Clinton discussing bin Laden day before 9/11 attack
- Gaza truce over, Israel soldier captured, 70 dead in Rafah shelling |
- Financial health: The four numbers to zero in on
- Ebola patient coming to U.S. as aid workers' health worsens
- Exposure of health workers weakens Africa's Ebola fight